Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities researchers at Leerink Partnrs lifted their FY2024 EPS estimates for Werewolf Therapeutics in a note issued to investors on Monday, November 11th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings per share of ($1.98) for the year, up from their previous estimate of ($2.07). The consensus estimate for Werewolf Therapeutics' current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Werewolf Therapeutics' Q4 2024 earnings at ($0.80) EPS, Q1 2025 earnings at ($1.17) EPS, Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($4.15) EPS, FY2026 earnings at ($3.40) EPS, FY2027 earnings at ($2.98) EPS and FY2028 earnings at ($2.56) EPS.
Werewolf Therapeutics Price Performance
Shares of Werewolf Therapeutics stock traded down $0.10 on Wednesday, reaching $2.05. The stock had a trading volume of 686,169 shares, compared to its average volume of 375,943. Werewolf Therapeutics has a fifty-two week low of $1.66 and a fifty-two week high of $8.19. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. The business's 50-day moving average price is $2.27 and its two-hundred day moving average price is $2.93.
Institutional Investors Weigh In On Werewolf Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC bought a new stake in Werewolf Therapeutics in the third quarter valued at approximately $29,000. Point72 DIFC Ltd acquired a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at approximately $34,000. Rhumbline Advisers bought a new stake in Werewolf Therapeutics during the 2nd quarter worth approximately $79,000. American Century Companies Inc. raised its holdings in Werewolf Therapeutics by 50.7% during the 2nd quarter. American Century Companies Inc. now owns 37,634 shares of the company's stock worth $92,000 after buying an additional 12,656 shares during the period. Finally, Murchinson Ltd. bought a new position in Werewolf Therapeutics in the second quarter valued at approximately $152,000. Institutional investors and hedge funds own 64.84% of the company's stock.
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Featured Articles
Before you consider Werewolf Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.
While Werewolf Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
